8月6日，诺和诺德公布2025年第二季度财报：
销售额为768.6亿丹麦克朗，同比增长13%，略低于市场预期的769.9亿丹麦克朗；
净利润为265亿丹麦克朗，同比增长32%，低于预期的270.1亿丹麦克朗；
息税前利润（EBIT）为334.5亿丹麦克朗，亦低于预期的344.5亿丹麦克朗。
核心产品方面，减重药Wegovy销售额达195.3亿丹麦克朗，超出市场预期（192亿）；糖尿病药Ozempic销售额为318亿丹麦克朗，略低于预期的322.2亿。
诺和诺德上半年净销售额为1549.44亿丹麦克朗，同比增长16%；净利润为555.37亿丹麦克朗，同比增长22%；稀释每股收益为12.49美元，同比增长23%。
诺和诺德表示，目前预计全年自由现金流将达到350亿至450亿丹麦克朗。诺和诺德预计，未来几年资本支出占销售额的比例将维持在低双位数区间（即10%-15%左右）。诺和诺德仍预计按固定汇率计算，全年销售额增长8%至14%。
财报发布后，诺和诺德夜盘涨超2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
